Når det administreres samtidig med levodopa og en aromatisk decarboxylasehæmmer (AADC- I) medfører det mere stabile plasmaniveauer af levodopa, idet metaboliseringen af levodopa til 3- methoxy- 4 - hydroxy- l- phenylalanin (3- OMD) reduceres.
Administered concomitantly with levodopa and an aromatic amino acid decarboxylase inhibitor (AADC-I), it leads to more stable plasma levels of levodopa by reducing metabolism of levodopa to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD).